Abstract
Rigorous management of the knowledge generated with the modeling techniques requires the exploration of different scenarios of interest via simulations, which can be used to inform many key decisions during drug development. This process, termed model-based drug development, is illustrated in three examples at different stages of drug development of erythropoiesis stimulating agents (ESA). Each of these examples reflects an actual situation with key decisions made based on the knowledge obtained from these models. One of the beneficial outcomes of the modeling and simulation approach is to elicit discussion in the development team on the unverifiable assumptions at each stage and to guide risk calculations in decision making. This approach can facilitate the development of better dosing regimens of new medicines, which may lead to enhanced benefit of the drug therapy and improvements in the quality of life of the patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Agarwal AK, Silver MR, Reed JE, Dhingra RK, Liu W, Varma N, Stehman-Breen C (2006) An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med 260:577–585
Agoram B, Heatherington AC, Gastonguay MR (2006) Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J 8:E552–E563
Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303–332
Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O (2010) A model-based approach to dose selection in early pediatric development. Clin Pharmacol Ther 87:294–302
Doshi S, Chow A, Pérez-Ruixo JJ (2010) Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. J Clin Pharmacol 50:75S–90S
Doshi S, Pérez-Ruixo JJ, Jang GR, Chow AT (2009) Pharmacokinetics of erythropoiesis-stimulating agents. In: Molineux G, Foote MA, Elliott S (eds) Erythropoietins and erythropoiesis: molecular, cellular, preclinical, and clinical biology, 2nd edn. Birkhäuser, Basel, Switzerland, pp 195–224
US Food and Drug Administration (2000) Guidance for industry. E11 clinical investigation of medicinal products in the pediatric population. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129477.pdf. Accessed 1 May 2010
US Food and Drug Administration (2003) Guidance for industry. exposure–response relationships – study design, data analysis, and regulatory applications. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072109.pdf. Accessed 1 May 2010
Erickson-Miller CL, Pelus LM, Lord KA (2000) Signaling induced by erythropoietin and stem cell factor in UT-7/EPO cells: transient versus sustained proliferation. Stem Cells 18:366–373
Hamrén B, Björk E, Sunzel M, Karlsson M (2008) Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther 84:228–235
Harker LA, Roskos LK, Marzec UM, Carter RA, Cherry JK, Sundell B, Cheung EN, Terry D, Sheridan W (2000) Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 95:2514–2522
Jolling K, Pérez-Ruixo JJ, Hemeryck A, Vermeulen A, Greway T (2005) Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 24:465–475
Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK (2005) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 26:295–306
Lazareno S, Birdsall NJM (1993) Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoff equations. Br J Clin Pharmacol 109:1110–1119
Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A, Olson K, Messer-Mann L, Maroni BJ (2002) Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 17:933–937
Mager DE, Woo S, Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24(1):16–24
Miller R, Ewy W, Corrigan BW, Ouellet D, Hermann D, Kowalski KG, Lockwood P, Koup JR, Donevan S, El-Kattan A, Li CS, Werth JL, Feltner DE, Lalonde RL (2005) How modeling and simulation have enhanced decision making in new drug development. J Pharmacokinet Pharmacodyn 32:185–197
Olsson-Gislekog P, Jacqmin P, Pérez-Ruixo JJ (2007) Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet 46:159–173
Olsson-Gisleskog P, Karlsson MO, Beal SL (2002) Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29:473–505
Pérez Ruixo JJ (2006) Optimizing the design of phase I studies of erythropoietin receptor agonist through mechanism-based PK/PD modeling and simulation. Population approach group in Europe meeting. http://userpage.fu-berlin.de/~page/. Accessed 1 May 2010
Pérez-Ruixo JJ, Kimko HC, Chow AT, Piotrovsky V, Krzyzanski W, Jusko WJ (2005) Population cell life span models for effects of drugs following indirect mechanism of action. J Pharmacokinet Pharmacodyn 32:767–793
Pérez-Ruixo JJ, de Ridder F, Kimko H, Samtani M, Cox E, Mohanty S, Vermeulen A (2008a) Simulation in clinical drug development. In: Bertau M, Mosekilde E, Westerhoff HV (eds) Biosimulation in drug development. Wiley-VCH, Germany, pp 3–24
Pérez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA, Zhou H, Yohrling J, Cohen A, Burggraaf J, Franson K, Davis H (2009) Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody™ construct CNTO 528 in healthy subjects. Clin Pharmacokinet 48:601–613
Pérez-Ruixo JJ, Krzyzanski W, Hing J (2008) Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin Pharmacokinet 47:399–415
Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB (2006) Pharmacokinetic and pharmacodynamic modeling of pegfilgrastim in healthy subjects. J Clin Pharmacol 46:747–757
Sharma A, Ebling WF, Jusko WJ (1998) Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 87:1577–1584
Sheiner L, Wakefield J (1999) Population modelling in drug development. Stat Methods Med Res 8:183–193
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Pérez-Ruixo, J.J., Doshi, S., Chow, A. (2011). Application of Pharmacokinetic–Pharmacodynamic Modeling and Simulation for Erythropoietic Stimulating Agents. In: Kimko, H., Peck, C. (eds) Clinical Trial Simulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7415-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7415-0_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7414-3
Online ISBN: 978-1-4419-7415-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)
